866-997-4948(US-Canada Toll Free)

Non-Small Cell Lung Cancer - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Dec 2015

Category :

Cancer

No. of Pages : 2029 Pages

Non-Small Cell Lung Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Non-Small Cell Lung Cancer - Pipeline Review, H2 2015, provides an overview of the Non-Small Cell Lung Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Non-Small Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 12
Non-Small Cell Lung Cancer Overview 13
Therapeutics Development 14
Non-Small Cell Lung Cancer - Therapeutics under Development by Companies 16
Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 37
Non-Small Cell Lung Cancer - Pipeline Products Glance 40
Non-Small Cell Lung Cancer - Products under Development by Companies 44
Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes 80
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 83
Non-Small Cell Lung Cancer - Therapeutics Assessment 326
Drug Profiles 375
Non-Small Cell Lung Cancer - Recent Pipeline Updates 1323
Non-Small Cell Lung Cancer - Dormant Projects 1927
Non-Small Cell Lung Cancer - Discontinued Products 1954
Non-Small Cell Lung Cancer - Product Development Milestones 1965
Appendix 1975

List of Tables
Number of Products under Development for Non-Small Cell Lung Cancer, H2 2015 67
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2015 68
Number of Products under Development by Companies, H2 2015 70
Number of Products under Development by Companies, H2 2015 (Contd..1) 71
Number of Products under Development by Companies, H2 2015 (Contd..2) 72
Number of Products under Development by Companies, H2 2015 (Contd..3) 73
Number of Products under Development by Companies, H2 2015 (Contd..4) 74
Number of Products under Development by Companies, H2 2015 (Contd..5) 75
Number of Products under Development by Companies, H2 2015 (Contd..6) 76
Number of Products under Development by Companies, H2 2015 (Contd..7) 77
Number of Products under Development by Companies, H2 2015 (Contd..8) 78
Number of Products under Development by Companies, H2 2015 (Contd..9) 79
Number of Products under Development by Companies, H2 2015 (Contd..10) 80
Number of Products under Development by Companies, H2 2015 (Contd..11) 81
Number of Products under Development by Companies, H2 2015 (Contd..12) 82
Number of Products under Development by Companies, H2 2015 (Contd..13) 83
Number of Products under Development by Companies, H2 2015 (Contd..14) 84
Number of Products under Development by Companies, H2 2015 (Contd..15) 85
Number of Products under Development by Companies, H2 2015 (Contd..16) 86
Number of Products under Development by Companies, H2 2015 (Contd..17) 87
Number of Products under Development by Companies, H2 2015 (Contd..18) 88
Number of Products under Development by Companies, H2 2015 (Contd..19) 89
Number of Products under Investigation by Universities/Institutes, H2 2015 90
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 91
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 92
Comparative Analysis by Late Stage Development, H2 2015 93
Comparative Analysis by Clinical Stage Development, H2 2015 94
Comparative Analysis by Early Stage Development, H2 2015 95
Comparative Analysis by Unknown Stage Development, H2 2015 96
Products under Development by Companies, H2 2015 97
Products under Development by Companies, H2 2015 (Contd..1) 98
Products under Development by Companies, H2 2015 (Contd..2) 99
Products under Development by Companies, H2 2015 (Contd..3) 100
Products under Development by Companies, H2 2015 (Contd..4) 101
Products under Development by Companies, H2 2015 (Contd..5) 102
Products under Development by Companies, H2 2015 (Contd..6) 103
Products under Development by Companies, H2 2015 (Contd..7) 104
Products under Development by Companies, H2 2015 (Contd..8) 105
Products under Development by Companies, H2 2015 (Contd..9) 106
Products under Development by Companies, H2 2015 (Contd..10) 107
Products under Development by Companies, H2 2015 (Contd..11) 108
Products under Development by Companies, H2 2015 (Contd..12) 109
Products under Development by Companies, H2 2015 (Contd..13) 110
Products under Development by Companies, H2 2015 (Contd..14) 111
Products under Development by Companies, H2 2015 (Contd..15) 112
Products under Development by Companies, H2 2015 (Contd..16) 113
Products under Development by Companies, H2 2015 (Contd..17) 114
Products under Development by Companies, H2 2015 (Contd..18) 115
Products under Development by Companies, H2 2015 (Contd..19) 116
Products under Development by Companies, H2 2015 (Contd..20) 117
Products under Development by Companies, H2 2015 (Contd..21) 118
Products under Development by Companies, H2 2015 (Contd..22) 119
Products under Development by Companies, H2 2015 (Contd..23) 120
Products under Development by Companies, H2 2015 (Contd..24) 121
Products under Development by Companies, H2 2015 (Contd..25) 122
Products under Development by Companies, H2 2015 (Contd..26) 123
Products under Development by Companies, H2 2015 (Contd..27) 124
Products under Development by Companies, H2 2015 (Contd..28) 125
Products under Development by Companies, H2 2015 (Contd..29) 126
Products under Development by Companies, H2 2015 (Contd..30) 127
Products under Development by Companies, H2 2015 (Contd..31) 128
Products under Development by Companies, H2 2015 (Contd..32) 129
Products under Development by Companies, H2 2015 (Contd..33) 130
Products under Development by Companies, H2 2015 (Contd..34) 131
Products under Development by Companies, H2 2015 (Contd..35) 132
Products under Investigation by Universities/Institutes, H2 2015 133
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 134
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 135
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H2 2015 136
Non-Small Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015 137
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H2 2015 138
Non-Small Cell Lung Cancer - Pipeline by Ability Pharma, SL, H2 2015 139
Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences, Inc., H2 2015 140
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Limited, H2 2015 141
Non-Small Cell Lung Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2015 142
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015 143
Non-Small Cell Lung Cancer - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015 144
Non-Small Cell Lung Cancer - Pipeline by Altimmune, Inc., H2 2015 145
Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corporation, H2 2015 146
Non-Small Cell Lung Cancer - Pipeline by Amgen Inc., H2 2015 147
Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H2 2015 148
Non-Small Cell Lung Cancer - Pipeline by AndroScience Corporation, H2 2015 149
Non-Small Cell Lung Cancer - Pipeline by APO-T B.V., H2 2015 150
Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc., H2 2015 151
Non-Small Cell Lung Cancer - Pipeline by Arch Biopartners, Inc., H2 2015 152
Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015 153
Non-Small Cell Lung Cancer - Pipeline by Arog Pharmaceuticals, Inc., H2 2015 154
Non-Small Cell Lung Cancer - Pipeline by ArQule, Inc., H2 2015 155
Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc., H2 2015 156
Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015 157
Non-Small Cell Lung Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015 158
Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H2 2015 159
Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 160
Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2015 161
Non-Small Cell Lung Cancer - Pipeline by ATLAB Pharma SAS, H2 2015 162
Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 163
Non-Small Cell Lung Cancer - Pipeline by Axelar AB, H2 2015 164
Non-Small Cell Lung Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2015 165
Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2015 166
Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H2 2015 167
Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2015 168
Non-Small Cell Lung Cancer - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015 169
Non-Small Cell Lung Cancer - Pipeline by Benitec Biopharma Limited, H2 2015 170
Non-Small Cell Lung Cancer - Pipeline by BerGenBio AS, H2 2015 171
Non-Small Cell Lung Cancer - Pipeline by Beta Pharma, Inc., H2 2015 172
Non-Small Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H2 2015 173
Non-Small Cell Lung Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2015 174
Non-Small Cell Lung Cancer - Pipeline by BIOCAD, H2 2015 175
Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H2 2015 176
Non-Small Cell Lung Cancer - Pipeline by BioLineRx, Ltd., H2 2015 177
Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H2 2015 178
Non-Small Cell Lung Cancer - Pipeline by Biothera, Inc., H2 2015 179
Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 180
Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical, Inc., H2 2015 181
Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015 182
Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences, Inc., H2 2015 183
Non-Small Cell Lung Cancer - Pipeline by CanBas Co., Ltd., H2 2015 184
Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2015 185
Non-Small Cell Lung Cancer - Pipeline by cCAM Biotherapeutics Ltd., H2 2015 186
Non-Small Cell Lung Cancer - Pipeline by Celgene Corporation, H2 2015 187
Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H2 2015 188
Non-Small Cell Lung Cancer - Pipeline by Cellceutix Corporation, H2 2015 189
Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015 190
Non-Small Cell Lung Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015 191
Non-Small Cell Lung Cancer - Pipeline by Cellectis S.A., H2 2015 192
Non-Small Cell Lung Cancer - Pipeline by Cellmid Limited, H2 2015 193
Non-Small Cell Lung Cancer - Pipeline by Celltrion, Inc., H2 2015 194
Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 195
Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2015 196
Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015 197
Non-Small Cell Lung Cancer - Pipeline by Clovis Oncology, Inc., H2 2015 198
Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2015 199
Non-Small Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015 200
Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015 201
Non-Small Cell Lung Cancer - Pipeline by CTI BioPharma Corp., H2 2015 202
Non-Small Cell Lung Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015 203
Non-Small Cell Lung Cancer - Pipeline by CureVac GmbH, H2 2015 204
Non-Small Cell Lung Cancer - Pipeline by CytRx Corporation, H2 2015 205
Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 206
Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H2 2015 207
Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC, Inc., H2 2015 208
Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma, LLC, H2 2015 209
Non-Small Cell Lung Cancer - Pipeline by DiNonA Inc., H2 2015 210
Non-Small Cell Lung Cancer - Pipeline by Domainex Limited, H2 2015 211
Non-Small Cell Lung Cancer - Pipeline by DormaTarg, Inc., H2 2015 212
Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2015 213
Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 214
Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals, Inc., H2 2015 215
Non-Small Cell Lung Cancer - Pipeline by EirGenix Inc., H2 2015 216
Non-Small Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H2 2015 217
Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2015 218
Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2015 219
Non-Small Cell Lung Cancer - Pipeline by Endocyte, Inc., H2 2015 220
Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H2 2015 221
Non-Small Cell Lung Cancer - Pipeline by EntreChem, S.L., H2 2015 222
Non-Small Cell Lung Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 223
Non-Small Cell Lung Cancer - Pipeline by Eudendron S.r.l., H2 2015 224
Non-Small Cell Lung Cancer - Pipeline by Exelixis, Inc., H2 2015 225
Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 226
Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2015 227
Non-Small Cell Lung Cancer - Pipeline by Fujifilm Corporation, H2 2015 228
Non-Small Cell Lung Cancer - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015 229
Non-Small Cell Lung Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2015 230
Non-Small Cell Lung Cancer - Pipeline by Genelux Corporation, H2 2015 231
Non-Small Cell Lung Cancer - Pipeline by Genentech, Inc., H2 2015 232
Non-Small Cell Lung Cancer - Pipeline by Genmab A/S, H2 2015 233
Non-Small Cell Lung Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2015 234
Non-Small Cell Lung Cancer - Pipeline by Genosco, H2 2015 235
Non-Small Cell Lung Cancer - Pipeline by Genzyme Corporation, H2 2015 236
Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences, Inc., H2 2015 237
Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015 238
Non-Small Cell Lung Cancer - Pipeline by Globeimmune, Inc., H2 2015 239
Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H2 2015 240
Non-Small Cell Lung Cancer - Pipeline by Glycotope GmbH, H2 2015 241
Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp., H2 2015 242
Non-Small Cell Lung Cancer - Pipeline by Gradalis Inc., H2 2015 243
Non-Small Cell Lung Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2015 244
Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 245
Non-Small Cell Lung Cancer - Pipeline by Heat Biologics, Inc., H2 2015 246
Non-Small Cell Lung Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2015 247
Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp., H2 2015 248
Non-Small Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2015 249
Non-Small Cell Lung Cancer - Pipeline by Hospira, Inc., H2 2015 250
Non-Small Cell Lung Cancer - Pipeline by Humanetics Corporation, H2 2015 251
Non-Small Cell Lung Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015 252
Non-Small Cell Lung Cancer - Pipeline by iCeutica, Inc., H2 2015 253
Non-Small Cell Lung Cancer - Pipeline by Ignyta, Inc., H2 2015 254
Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp., H2 2015 255
Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals Inc., H2 2015 256
Non-Small Cell Lung Cancer - Pipeline by ImmunGene, Inc., H2 2015 257
Non-Small Cell Lung Cancer - Pipeline by ImmunoFrontier, Inc., H2 2015 258
Non-Small Cell Lung Cancer - Pipeline by ImmunoGen, Inc., H2 2015 259
Non-Small Cell Lung Cancer - Pipeline by Immunome Inc., H2 2015 260
Non-Small Cell Lung Cancer - Pipeline by Immunomedics, Inc., H2 2015 261
Non-Small Cell Lung Cancer - Pipeline by Incanthera Ltd., H2 2015 262
Non-Small Cell Lung Cancer - Pipeline by Incuron, LLC, H2 2015 263
Non-Small Cell Lung Cancer - Pipeline by Incyte Corporation, H2 2015 264
Non-Small Cell Lung Cancer - Pipeline by Inflection Biosciences Limited, H2 2015 265
Non-Small Cell Lung Cancer - Pipeline by Intezyne, Inc, H2 2015 266
Non-Small Cell Lung Cancer - Pipeline by Inventiva SAS, H2 2015 267
Non-Small Cell Lung Cancer - Pipeline by IO Biotech ApS, H2 2015 268
Non-Small Cell Lung Cancer - Pipeline by Io Therapeutics, Inc., H2 2015 269
Non-Small Cell Lung Cancer - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 270
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015 271
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2015 272
Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2015 273
Non-Small Cell Lung Cancer - Pipeline by Juno Therapeutics Inc., H2 2015 274
Non-Small Cell Lung Cancer - Pipeline by Kadmon Corporation, LLC, H2 2015 275
Non-Small Cell Lung Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2015 276
Non-Small Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2015 277
Non-Small Cell Lung Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015 278
Non-Small Cell Lung Cancer - Pipeline by Kura Oncology, Inc., H2 2015 279
Non-Small Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 280
Non-Small Cell Lung Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2015 281
Non-Small Cell Lung Cancer - Pipeline by Loxo Oncology, Inc., H2 2015 282
Non-Small Cell Lung Cancer - Pipeline by Mabion SA, H2 2015 283
Non-Small Cell Lung Cancer - Pipeline by MacroGenics, Inc., H2 2015 284
Non-Small Cell Lung Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015 285
Non-Small Cell Lung Cancer - Pipeline by MedImmune, LLC, H2 2015 286
Non-Small Cell Lung Cancer - Pipeline by Merck & Co., Inc., H2 2015 287
Non-Small Cell Lung Cancer - Pipeline by Merck KGaA, H2 2015 288
Non-Small Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 289
Non-Small Cell Lung Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2015 290
Non-Small Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 291
Non-Small Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc., H2 2015 292
Non-Small Cell Lung Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2015 293
Non-Small Cell Lung Cancer - Pipeline by Modulation Therapeutics, Inc., H2 2015 294
Non-Small Cell Lung Cancer - Pipeline by MolMed S.p.A., H2 2015 295
Non-Small Cell Lung Cancer - Pipeline by Morphotek, Inc., H2 2015 296
Non-Small Cell Lung Cancer - Pipeline by Multimmune GmbH, H2 2015 297
Non-Small Cell Lung Cancer - Pipeline by Mycenax Biotech Inc., H2 2015 298
Non-Small Cell Lung Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2015 299
Non-Small Cell Lung Cancer - Pipeline by Natco Pharma Limited, H2 2015 300
Non-Small Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2015 301
Non-Small Cell Lung Cancer - Pipeline by Nemucore Medical Innovations, Inc., H2 2015 302
Non-Small Cell Lung Cancer - Pipeline by NeoPharm Co., Ltd., H2 2015 303
Non-Small Cell Lung Cancer - Pipeline by Netris Pharma S.A.S., H2 2015 304
Non-Small Cell Lung Cancer - Pipeline by NewLink Genetics Corporation, H2 2015 305
Non-Small Cell Lung Cancer - Pipeline by Nimbus Therapeutics, LLC, H2 2015 306
Non-Small Cell Lung Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2015 307
Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H2 2015 308
Non-Small Cell Lung Cancer - Pipeline by NuCana BioMed Limited, H2 2015 309
Non-Small Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015 310
Non-Small Cell Lung Cancer - Pipeline by Oncobiologics, Inc., H2 2015 311
Non-Small Cell Lung Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2015 312
Non-Small Cell Lung Cancer - Pipeline by Oncology Research International Limited, H2 2015 313
Non-Small Cell Lung Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015 314
Non-Small Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015 315
Non-Small Cell Lung Cancer - Pipeline by Oncothyreon Inc., H2 2015 316
Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 317
Non-Small Cell Lung Cancer - Pipeline by Onxeo SA, H2 2015 318
Non-Small Cell Lung Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 319
Non-Small Cell Lung Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2015 320
Non-Small Cell Lung Cancer - Pipeline by Oscotec Inc., H2 2015 321
Non-Small Cell Lung Cancer - Pipeline by OSE Pharma SA, H2 2015 322
Non-Small Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2015 323
Non-Small Cell Lung Cancer - Pipeline by Panacea Biotec Limited, H2 2015 324
Non-Small Cell Lung Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015 325
Non-Small Cell Lung Cancer - Pipeline by Pfizer Inc., H2 2015 326
Non-Small Cell Lung Cancer - Pipeline by Pharma Mar, S.A., H2 2015 327
Non-Small Cell Lung Cancer - Pipeline by Philogen S.p.A., H2 2015 328
Non-Small Cell Lung Cancer - Pipeline by Pique Therapeutics, H2 2015 329
Non-Small Cell Lung Cancer - Pipeline by Plexxikon Inc., H2 2015 330
Non-Small Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 331
Non-Small Cell Lung Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2015 332
Non-Small Cell Lung Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015 333
Non-Small Cell Lung Cancer - Pipeline by Purdue Pharma L.P., H2 2015 334
Non-Small Cell Lung Cancer - Pipeline by Qu Biologics Inc., H2 2015 335
Non-Small Cell Lung Cancer - Pipeline by Reata Pharmaceuticals, Inc., H2 2015 336
Non-Small Cell Lung Cancer - Pipeline by Recombio S.L, H2 2015 337
Non-Small Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015 338
Non-Small Cell Lung Cancer - Pipeline by Samyang Holdings Corporation, H2 2015 339
Non-Small Cell Lung Cancer - Pipeline by Sanofi, H2 2015 340
Non-Small Cell Lung Cancer - Pipeline by Sapvax, H2 2015 341
Non-Small Cell Lung Cancer - Pipeline by Sareum Holdings Plc, H2 2015 342
Non-Small Cell Lung Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2015 343
Non-Small Cell Lung Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd, H2 2015 344
Non-Small Cell Lung Cancer - Pipeline by Shionogi & Co., Ltd., H2 2015 345
Non-Small Cell Lung Cancer - Pipeline by SignPath Pharma Inc, H2 2015 346
Non-Small Cell Lung Cancer - Pipeline by Sirnaomics, Inc., H2 2015 347
Non-Small Cell Lung Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2015 348
Non-Small Cell Lung Cancer - Pipeline by Sotio a.s., H2 2015 349
Non-Small Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 350
Non-Small Cell Lung Cancer - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015 351
Non-Small Cell Lung Cancer - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2015 352
Non-Small Cell Lung Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2015 353
Non-Small Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 354
Non-Small Cell Lung Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 355
Non-Small Cell Lung Cancer - Pipeline by SuviCa Inc., H2 2015 356
Non-Small Cell Lung Cancer - Pipeline by Symphogen A/S, H2 2015 357
Non-Small Cell Lung Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 358
Non-Small Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015 359
Non-Small Cell Lung Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015 360
Non-Small Cell Lung Cancer - Pipeline by TC BioPharm Limited, H2 2015 361
Non-Small Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 362
Non-Small Cell Lung Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 363
Non-Small Cell Lung Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H2 2015 364
Non-Small Cell Lung Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015 365
Non-Small Cell Lung Cancer - Pipeline by Transgene SA, H2 2015 366
Non-Small Cell Lung Cancer - Pipeline by Ultimovacs AS, H2 2015 367
Non-Small Cell Lung Cancer - Pipeline by VasGene Therapeutics, Inc., H2 2015 368
Non-Small Cell Lung Cancer - Pipeline by Vaxon Biotech, H2 2015 369
Non-Small Cell Lung Cancer - Pipeline by Verastem, Inc., H2 2015 370
Non-Small Cell Lung Cancer - Pipeline by Verlyx Pharma Inc., H2 2015 371
Non-Small Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 372
Non-Small Cell Lung Cancer - Pipeline by VG Life Sciences, Inc., H2 2015 373
Non-Small Cell Lung Cancer - Pipeline by Vichem Chemie Research Ltd., H2 2015 374
Non-Small Cell Lung Cancer - Pipeline by Viralytics Ltd., H2 2015 375
Non-Small Cell Lung Cancer - Pipeline by XBiotech USA, Inc., H2 2015 376
Non-Small Cell Lung Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H2 2015 377
Non-Small Cell Lung Cancer - Pipeline by Zyngenia, Inc., H2 2015 378
Assessment by Monotherapy Products, H2 2015 379
Assessment by Combination Products, H2 2015 380
Number of Products by Stage and Target, H2 2015 382
Number of Products by Stage and Mechanism of Action, H2 2015 407
Number of Products by Stage and Route of Administration, H2 2015 425
Number of Products by Stage and Molecule Type, H2 2015 427
Non-Small Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H2 2015 1375
Non-Small Cell Lung Cancer - Dormant Projects, H2 2015 1979
Non-Small Cell Lung Cancer - Dormant Projects (Contd..1), H2 2015 1980
Non-Small Cell Lung Cancer - Dormant Projects (Contd..2), H2 2015 1981
Non-Small Cell Lung Cancer - Dormant Projects (Contd..3), H2 2015 1982
Non-Small Cell Lung Cancer - Dormant Projects (Contd..4), H2 2015 1983
Non-Small Cell Lung Cancer - Dormant Projects (Contd..5), H2 2015 1984
Non-Small Cell Lung Cancer - Dormant Projects (Contd..6), H2 2015 1985
Non-Small Cell Lung Cancer - Dormant Projects (Contd..7), H2 2015 1986
Non-Small Cell Lung Cancer - Dormant Projects (Contd..8), H2 2015 1987
Non-Small Cell Lung Cancer - Dormant Projects (Contd..9), H2 2015 1988
Non-Small Cell Lung Cancer - Dormant Projects (Contd..10), H2 2015 1989
Non-Small Cell Lung Cancer - Dormant Projects (Contd..11), H2 2015 1990
Non-Small Cell Lung Cancer - Dormant Projects (Contd..12), H2 2015 1991
Non-Small Cell Lung Cancer - Dormant Projects (Contd..13), H2 2015 1992
Non-Small Cell Lung Cancer - Dormant Projects (Contd..14), H2 2015 1993
Non-Small Cell Lung Cancer - Dormant Projects (Contd..15), H2 2015 1994
Non-Small Cell Lung Cancer - Dormant Projects (Contd..16), H2 2015 1995
Non-Small Cell Lung Cancer - Dormant Projects (Contd..17), H2 2015 1996
Non-Small Cell Lung Cancer - Dormant Projects (Contd..18), H2 2015 1997
Non-Small Cell Lung Cancer - Dormant Projects (Contd..19), H2 2015 1998
Non-Small Cell Lung Cancer - Dormant Projects (Contd..20), H2 2015 1999
Non-Small Cell Lung Cancer - Dormant Projects (Contd..21), H2 2015 2000
Non-Small Cell Lung Cancer - Dormant Projects (Contd..22), H2 2015 2001
Non-Small Cell Lung Cancer - Dormant Projects (Contd..23), H2 2015 2002
Non-Small Cell Lung Cancer - Dormant Projects (Contd..24), H2 2015 2003
Non-Small Cell Lung Cancer - Dormant Projects (Contd..25), H2 2015 2004
Non-Small Cell Lung Cancer - Dormant Projects (Contd..26), H2 2015 2005
Non-Small Cell Lung Cancer - Discontinued Products, H2 2015 2006
Non-Small Cell Lung Cancer - Discontinued Products (Contd..1), H2 2015 2007
Non-Small Cell Lung Cancer - Discontinued Products (Contd..2), H2 2015 2008
Non-Small Cell Lung Cancer - Discontinued Products (Contd..3), H2 2015 2009
Non-Small Cell Lung Cancer - Discontinued Products (Contd..4), H2 2015 2010
Non-Small Cell Lung Cancer - Discontinued Products (Contd..5), H2 2015 2011
Non-Small Cell Lung Cancer - Discontinued Products (Contd..6), H2 2015 2012
Non-Small Cell Lung Cancer - Discontinued Products (Contd..7), H2 2015 2013
Non-Small Cell Lung Cancer - Discontinued Products (Contd..8), H2 2015 2014
Non-Small Cell Lung Cancer - Discontinued Products (Contd..9), H2 2015 2015
Non-Small Cell Lung Cancer - Discontinued Products (Contd..10), H2 2015 2016

List of Figures
Number of Products under Development for Non-Small Cell Lung Cancer, H2 2015 67
Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2015 68
Number of Products under Development by Companies, H2 2015 69
Number of Products under Investigation by Universities/Institutes, H2 2015 90
Comparative Analysis by Late Stage Development, H2 2015 93
Comparative Analysis by Clinical Stage Development, H2 2015 94
Comparative Analysis by Early Stage Products, H2 2015 95
Assessment by Monotherapy Products, H2 2015 379
Assessment by Combination Products, H2 2015 380
Number of Products by Top 10 Targets, H2 2015 381
Number of Products by Stage and Top 10 Targets, H2 2015 381
Number of Products by Top 10 Mechanism of Actions, H2 2015 406
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 406
Number of Products by Top 10 Routes of Administration, H2 2015 424
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 424
Number of Products by Top 10 Molecule Types, H2 2015 426
Number of Products by Stage and Top 10 Molecule Types, H2 2015 426

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *